Pfizer says its updated COVID-19 booster significantly revved up adults' virus-fighting antibodies.
FILE- A Pfizer logo is shown at their global supply Kalamazoo manufacturing plant in Portage, Mich., on Dec. 11, 2020. Pfizers updated COVID-19 booster significantly revved up adults virus-fighting antibodies, the company said Friday, Nov. 4, 2022 -- early findings from a rigorous study of the new shots.
Pfizer said people 55 and older who got the omicron-targeting booster had four-fold higher antibody levels than those given an extra dose of the original vaccine. A hint: A month after receiving the new booster, antibody levels in people 55 and older had jumped 13 times higher than before the extra dose. Younger adults saw a 9.5-fold jump, Pfizer and its partner BioNTech said. It had been about 11 months since the study participants’ last vaccination.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Pfizer, BioNTech launch phase 1 trial on combined COVID-19 and flu vaccinePfizer and BioNTech have launched a clinical trial on a vaccine targeting both COVID-19 and influenza, the companies announced Thursday.
Baca lebih lajut »
Pfizer study says updated COVID boosters rev up protectionPfizer said people 55 and older who got the omicron-targeting booster had four-fold higher antibody levels than those given an extra dose of the original vaccine.
Baca lebih lajut »
Pfizer study says updated COVID vaccine boosters rev up protectionPfizer's updated COVID-19 booster significantly revved up adults' virus-fighting antibodies, the company said Friday, releasing early findings from a rigorous study of the new shots.
Baca lebih lajut »
Pfizer says new Covid booster works better against omicron strains than old one in studyPfizer Inc.’s bivalent vaccine bolstered protective antibodies against the dominant omicron strains substantially more than its original booster in people older than 55, according to a compan…
Baca lebih lajut »
Pfizer, BioNTech launch combo COVID-flu vaccine studyPfizer and BioNTech aim to enroll 180 U.S. volunteers between the ages of 18 and 64 for an early-stage trial to assess the safety, efficacy and optimal dosage.
Baca lebih lajut »
Pfizer announces testing for combination vaccine to target COVID and fluThe drugmakers that developed the first COVID-19 vaccines hope to save Americans from an extra trip to the pharmacy with a single shot that targets both COVID and the flu.
Baca lebih lajut »